# Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

> **NCT01455090** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 320 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** BMS-650032
- **DRUG:** BMS-790052
- **DRUG:** BMS-791325
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01455090
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-30
- **Primary completion:** 2014-03-31
- **Final completion:** 2015-07-31
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2017-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01455090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01455090, "Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01455090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*